Genetron Health Announces Strategic Collaboration with DARUI on GENETRON S5 Platform


BEIJING, 20 May 2020 - Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that it has joined forces with DARUI. The partnership will support DARUI at developing pathogenic microorganism detection products and applying for registration of reagent kits using the NGS sequencer GENETRON S5 (Registration Number 20193220820). Featuring diverse application scenarios and open R&D accessibility, GENETRON S5 has been widely used in various areas, such as detecting tumors, genetic diseases and pathogenic microorganisms.

Seven IVD products of Genetron Health have received NMPA approval for clinical application, including the GENETRON S5. Its products cover three major technology platforms: dPCR, qPCR, and NGS. The NGS platforms, in particular, provide flexible combinations of products with low, medium and high-throughput. Genetron Health also offers overall R&D and commercialization solutions for in vitro diagnostic technologies available on multiple technology platforms and in various application scenarios, by fully exploring and tapping into the unique strength of each technology platform.

“We are very pleased to enter into this strategic partnership with DARUI, where each party can leverage its strength to enhance cooperation in the field of pathogenic microorganism detection. In expanding its IVD product portfolio, Genetron Health is committed to building highly open and flexible technology platforms, and strives to provide its partners with cost-effective and efficient product R&D solutions. In the outbreak of the COVID-19 pandemic, we are interested in taking preemptive moves to develop research and testing capabilities in response to major public health emergency events”, said Wang Sizhen, CEO of Genetron Health.

“We look forward to working with Genetron Health, the leader in the field of cancer molecular diagnostics. We are not only attracted by the stellar performance of GENETRON S5 platform and its potential for new product development, but also impressed by the Genetron Health’s R&D expertise, efficient commercialization capability and open-minded business sense, which will provide outstanding innovation platforms and plans for its partners”, said Li Ming, Chairman of DARUI.

It is worth noting that the first collaboration between GENETRON S5 platform and Darui pathogenic microorganism detection kits was at Wuhan Huoshenshan Hospital to combat COVID-19 at the frontline. Their joint operation, rapid sample testing, and reporting won precious time for infected patients in critical conditions and provided comprehensive testing information for clinical study purposes. 


Founded in 2003, Guangzhou DARUI Biotechnology Co.,Ltd is one of the earliest high-tech enterprise oriented in molecular diagnostic techniques. It was listed on the National Equities Exchange and Quotations on July 9, 2015.

The headquarters of DARUI is located in Science Park, Guangzhou, China. It consists of scientific research center which covers an area of 7300m2, and class 10,000 and 100,000 clean manufacturing workshops which covers an area of 1200 m2. The base is equipped with various advanced scientific research instruments and production facilities. It has reached the level of the leading biotech enterprises.

Print Page
Contact IR